249 related articles for article (PubMed ID: 8444513)
1. Acetylation of dapsone by human whole blood.
Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM; Gharaibeh NS
Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):18-22. PubMed ID: 8444513
[TBL] [Abstract][Full Text] [Related]
2. Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone resistant leprosy.
Raj PP; Aschhoff M; Lilly L; Balakrishnan S
Indian J Lepr; 1988 Jul; 60(3):400-6. PubMed ID: 3058828
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva.
Lammintausta K; Kangas L; Lammintausta R
Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):159-63. PubMed ID: 447435
[TBL] [Abstract][Full Text] [Related]
4. N-acetylation phenotyping using dapsone in a Jordanian population.
Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
[TBL] [Abstract][Full Text] [Related]
5. Acetylator phenotype in Iraqi patients with atopic dermatitis.
Najim RA; Al-Waiz MM; Al-Razzuqi RA
Dermatol Online J; 2006 Dec; 12(7):1. PubMed ID: 17459287
[TBL] [Abstract][Full Text] [Related]
6. Blood DDS levels and acetylation rates of sulphadimidine in leprosy patients.
Balakrishnan S; Ramu G
Lepr India; 1977 Jan; 49(1):59-64. PubMed ID: 330945
[TBL] [Abstract][Full Text] [Related]
7. N-acetylation polymorphism of dapsone in a Japanese population.
Horai Y; Ishizaki T
Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of acetyl CoA: arylamine N-acetyltransferase from rapid and slow acetylator human liver.
Kilbane AJ; Petroff T; Weber WW
Drug Metab Dispos; 1991; 19(2):503-7. PubMed ID: 1676662
[TBL] [Abstract][Full Text] [Related]
9. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
[TBL] [Abstract][Full Text] [Related]
10. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
Najim RA; Farid YY; Samad TA; Shihab SA
East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
[TBL] [Abstract][Full Text] [Related]
11. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
[TBL] [Abstract][Full Text] [Related]
12. N-acetylation phenotyping with dapsone in a mainland Chinese population.
Horai Y; Zhou HH; Zhang LM; Ishizaki T
Br J Clin Pharmacol; 1988 Jan; 25(1):81-7. PubMed ID: 3370194
[TBL] [Abstract][Full Text] [Related]
13. Antinuclear antibodies related to acetylator phenotype in mice.
Tannen RH; Weber WW
J Pharmacol Exp Ther; 1980 Jun; 213(3):485-90. PubMed ID: 6970809
[TBL] [Abstract][Full Text] [Related]
14. N-acetylation of drugs. Pharmacogenetic studies in rabbits selected for their acetylator characteristics.
Weber WW; Miceli JN; Hearse DJ; Drummond GS
Drug Metab Dispos; 1976; 4(1):94-101. PubMed ID: 3408
[TBL] [Abstract][Full Text] [Related]
15. Influence of age, sex and body weight on the dapsone acetylation phenotype.
Philip PA; Gayed SL; Rogers HJ; Crome P
Br J Clin Pharmacol; 1987 Jun; 23(6):709-13. PubMed ID: 3606931
[TBL] [Abstract][Full Text] [Related]
16. N-acetylation pharmacogenetics. Michaelis-Menten constants for arylamine drugs as predictors of their N-acetylation rates in vivo.
Andres HH; Weber WW
Drug Metab Dispos; 1986; 14(4):382-5. PubMed ID: 2873982
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].
Gawrońska-Szklarz B; Górnik W; Kutrzeba J; Wójcicki J; Zakrzewski J
Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):921-3. PubMed ID: 1284448
[TBL] [Abstract][Full Text] [Related]
18. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
Bluhm RE; Adedoyin A; McCarver DG; Branch RA
Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
[TBL] [Abstract][Full Text] [Related]
19. Biochemical investigation of the basis for the genetic N-acetylation polymorphism in the inbred hamster.
Hein DW; Kirlin WG; Ferguson RJ; Weber WW
J Pharmacol Exp Ther; 1985 Aug; 234(2):358-64. PubMed ID: 3874952
[TBL] [Abstract][Full Text] [Related]
20. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
